Stem Cells http://www.stemcellsportal.com/
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ludwig, H.
Right arrow Articles by Fritz, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ludwig, H.
Right arrow Articles by Fritz, E.

Stem Cells, Vol 11, 348-355, Copyright © 1993 by AlphaMed Press

REVIEWS

Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma

H Ludwig, M Pecherstorfer, C Leitgeb and E Fritz
1st Department of Medicine and Medical Oncology, Wilhelminenspital, Vienna, Austria.

Recombinant human erythropoietin (rHuEPO) improves chronic anemia of cancer, but the proportion of patients who respond favorably to the treatment varies depending on the type of neoplasia. Preliminary data of the two malignancies with the highest response rates, namely, multiple myeloma and squamous cell carcinoma, are reported. Twenty patients with multiple myeloma and 14 with squamous cell carcinoma, who had presented with hemoglobin levels < 11 g/dl, were treated with rHuEPO, 150 U/kg, three times/week. Response, defined as an increase of at least 2 g/dl hemoglobin within 12 weeks, was achieved by 15 myeloma patients (75%) and 11 patients with squamous cell carcinoma (79%). Tolerance of the treatment was excellent. The WHO performance status and quality of life improved in responders. The remarkably low levels of endogenous EPO in our patients with squamous cell carcinoma, most of whom had been treated with cisplatin-or carboplatin-containing regimens, suggest that anemia in these cases had been at least partly chemotherapy induced. In myeloma patients, the blunted EPO response to the anemic condition may have been partly caused by subclinical tubular insufficiency induced by toxic paraproteins. Future studies should aim to elucidate factors which are responsible for the inability of some patients to respond to rHuEPO treatment, even though in multiple myeloma and squamous cell carcinoma these non-responders are a small minority.


This article has been cited by other articles:


Home page
 JCOHome page
T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al.
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
T. Fjornes
Response and prediction of response to recombinant human erythropoietin in patients with solid tumors and platinum-associated anemia
Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 22 - 31.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 1993 by AlphaMed Press.